A Randomized Pilot Phase I Study of Immunization With Modified CEA (CAP1-6D) Peptide In Patients With Locally Advanced Or Surgically Resected Adenocarcinoma of the Pancreas.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs CAP1-6D peptide vaccine (Primary) ; CEA vaccine
- Indications Pancreatic cancer
- Focus Adverse reactions
- 16 Apr 2014 Biomarkers information updated
- 19 Jun 2012 Status changed from active, no longer recruiting to completed.
- 04 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.